ASH sets up multiple anti-BCMA opportunities for MM patients

BCMA-targeted agents to treat multiple myeloma once again took center stage at ASH as more companies and modalities continue to pile into the space, setting up several options for patients and physicians based on trade-offs in efficacy, toxicity and convenience. The leader in the space, GSK, was absent as it prepares its BLA for ADC belantamab mafodotin.

At least seven companies presented data at the American Society of Hematology meeting over the weekend for CAR T and bispecific immune-triggering mAbs as they try to find a niche of multiple myeloma (MM) patients who could benefit...